Blog
RSS FeedPosted by Michael Wonder on 23 Jan 2025
EU-HTA: maintaining the achievements of AMNOG
20 January 2025 - IQWiG welcomes the fact that the adjustments to the AMNOG procedure planned for the integration with European ...
Posted by Michael Wonder on 16 Dec 2024
Findings from the EUnetHTA 21 project for EU-HTA from 2025
12 December 2024 - The results from EUnetHTA 21 provide insights for future cooperation in EU-HTA: participants from IQWiG and ...
Posted by Michael Wonder on 09 Aug 2024
BioMarin announces updated strategy for Roctavian to focus on US, Germany and Italy
5 August 2024 - Strategic focus will reduce operating expenses with the goal of achieving Roctavian profitability by end of 2025. ...
Posted by Michael Wonder on 27 Jul 2023
Access and availability: Why are Europeans finding it hard to get the new medicines they need?
27 July 2023 - Patients are struggling to get hold of the new medicines they desperately need and ask what ...
Posted by Michael Wonder on 03 Jul 2023
EU-HTA: G-BA coordinates parallel scientific consultations for manufacturers from September
3 July 2023 - From 2025, a systematic evaluation of clinical studies for new medicinal products and medical devices will ...
Posted by Michael Wonder on 13 Jun 2023
Planned revision of EU pharmaceutical legislation: early market access and robust evidence need not remain a contradiction in terms
13 June 2023 - On 26 April, the EU Commission presented a proposal for the revision of pharmaceutical legislation in ...
Posted by Michael Wonder on 07 Dec 2022
Differences in evidentiary requirements between European Medicines Agency and European health technology assessment of oncology drugs—can alignment be enhanced?
5 December 2022 - National health technology assessments across Europe show differences in evidentiary requirements from assessments by the EMA, affecting ...
Posted by Michael Wonder on 23 Aug 2022
The EU HTA regulation: a new frontier for access to innovative technologies
23 August 2022 - A new health technology regulation is due to be applied to help EU countries determine the effectiveness ...
Posted by Michael Wonder on 19 Jun 2022
EU HTA regulation: international preparatory meeting in Cologne
17 June 2022 - At the invitation of IQWiG, 41 envoys from European HTA organisations and two from the EU ...
Posted by Michael Wonder on 29 May 2022
EUnetHTA relative effectiveness assessments: efforts to increase usability, transparency and inclusiveness
26 May 2022 - The objective of the European Network for Health Technology Assessment (EUnetHTA) Joint Action 3 (JA3) was to ...
Posted by Michael Wonder on 21 Apr 2022
European collaboration on health technology assessment: looking backward and forward
19 April 2022 - The establishment of health technology assessment has been an important topic in Europe for many years. ...
Posted by Michael Wonder on 04 Apr 2022
Bluebird Bio has serious cash flow concerns; inability to strike reimbursement deals in Europe partly to blame
3 April 2022 - Bluebird bio is a highly innovative biotechnology company which develops gene therapies for several rare genetic ...
Posted by Michael Wonder on 26 Feb 2022
COVID-19 vaccines: individual patient data should be submitted to the European Medicines Agency
24 February 2022 - An interesting letter to the Editor of the BMJ from the Head of Drug Assessment at ...
Posted by Michael Wonder on 20 Feb 2022
Assessing transferability in systematic reviews of health economic evaluations – a review of methodological guidance
20 February 2022 - For assessing cost effectiveness, health technology assessment organisations may use primary economic evaluations or systematic reviews of ...
Posted by Michael Wonder on 02 Feb 2022
New EU regulation on health technology assessment of cancer medicines
1 February 2022 - On Dec 15, 2021, the EU adopted a new regulation to harmonise health technology assessment of new ...